A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-Acute Lymphoblastic Leukemia Patients.

Trial Profile

A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-Acute Lymphoblastic Leukemia Patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2011 Results, for the first time, have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top